Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

The Singapore Chinese Health Study (SCHS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03356340
Recruitment Status : Active, not recruiting
First Posted : November 29, 2017
Last Update Posted : August 20, 2021
National University, Singapore
Information provided by (Responsible Party):
Woon-Puay Koh, National University, Singapore

Brief Summary:
The "Singapore Chinese Health Study" is a cohort study established by the Department of Epidemiology and Public Health in National University of Singapore, together with collaborators from several universities in the United States of America. This is a long-term study to help doctors and scientists understand the influence of diet, lifestyle and environment on the development of common diseases among Singaporean men and women. This includes cancer, heart disease, stroke, dementia, osteoporosis, high cholesterol and diabetes. The aim is to help us understand the causes of these diseases and to discover effective and efficient approaches for prevention and treatment.

Condition or disease
Cancer End Stage Renal Disease Diabetes Cardiovascular Diseases

Detailed Description:
The cohort consists of more than 60,000 men and women who were enrolled in the Singapore Chinese Health Study during 1993-1998. At the time of enrollment, participants were interviewed in-person regarding their dietary habits and other lifestyle factors. About half of them also donated small amounts of blood and urine for research between 2000 and 2004.

Layout table for study information
Study Type : Observational
Actual Enrollment : 63257 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Singapore Chinese Health Study
Actual Study Start Date : April 1, 1993
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : December 31, 2025

Primary Outcome Measures :
  1. Cancer incidence [ Time Frame: 1993 to 2025 ]
    Linkage to national cancer registry

  2. End-stage Renal Disease [ Time Frame: 1993 to 2025 ]
    Linkage to national renal registry

Biospecimen Retention:   Samples With DNA
Beginning in April 1994, a 3% random sample of enrollees were re-contacted for donation of blood/buccal cells and spot urine specimens. In January 2001, the accrual of biospecimens was extended to include all consenting cohort enrollees. Hitherto, biospecimens have been collected from about 32,800 subjects (28,439 bloods, 4,438 buccal cells, 31,201 urines), representing a consent rate of about 60%.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study was established between April 1993 and December 1998 through the recruitment of a residential cohort of 63,257 Chinese men (n=27,959) and women (n=35,298), who were aged 45-74 years, and residing in public housing estates.

Inclusion Criteria:

  • Housing estate residents, ages 45-74 years, Chinese

Exclusion Criteria:

  • None
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Woon-Puay Koh, Professor, National University, Singapore Identifier: NCT03356340    
Other Study ID Numbers: SCHS
First Posted: November 29, 2017    Key Record Dates
Last Update Posted: August 20, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Cardiovascular Diseases
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency